1 – 8 of 8
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
(
- Contribution to journal › Scientific review
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
(
- Contribution to journal › Scientific review
- 2020
-
Mark
A European Academy of Neurology guideline on medical management issues in dementia
(
- Contribution to journal › Article
- 2017
-
Mark
Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota
(
- Contribution to journal › Article
- 2011
-
Mark
Regional Differences in Effects of APOE epsilon 4 on Cognitive Impairment in Non-Demented Subjects
(
- Contribution to journal › Article
- 2009
-
Mark
White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study
(
- Contribution to journal › Article
- 2008
-
Mark
Development of screening guidelines and clinical criteria for predementia Alzheimer's disease
(
- Contribution to journal › Article